Cannabis in post-traumatic stress disorder

TL;DR

• Nabilone 0.5–3 mg (synthetic THC): reduces nightmares (Fraser 2009).
• Oral CBD 300–600 mg: reduces symptoms in 91% (Bonn-Miller 2021, open-label).
• First RCT (Bonn-Miller 2021): no THC superiority over placebo at 12 weeks.
• CB1 blockade strengthens fear memory — hypothesis basis.

Swiss access

Nabilone (Cesamet) is not routinely available in Switzerland. Physician-prescribed cannabis tincture (Bedrocan, Sativex) via FOPH exceptional authorisation has been simplified since 08/2022.

Neurobiological mechanisms of the endocannabinoid system in PTSD

Neurobiological research suggests a close link between the endocannabinoid system and the development of trauma-related disorders. In individuals affected by post-traumatic stress disorder, imaging techniques and laboratory analyses frequently show an altered density of CB1 receptors in the brain, particularly in regions such as the amygdala and the hippocampus. These areas are crucially responsible for processing fear, threat, and emotional memories. A chronic deficiency of endogenous cannabinoids could contribute to traumatic memory contents not being adequately processed and extinguished, leading to typical intrusions.

Phytocannabinoids such as THC and CBD target the same receptors and thus intervene in this disrupted regulation. While THC primarily acts as a partial agonist at the CB1 receptor and can thereby dampen the overactivity of the amygdala, CBD modulates various signalling systems, including serotonin receptors. This interaction is seen as a potential starting point to support so-called extinction — the active unlearning of fear responses — to be supported. Nevertheless, the clinical data on the long-term stability of these effects remains insufficient, which is why neurobiological research in this area continues to face major methodological challenges.

• High density of CB1 receptors in fear-processing brain regions such as the amygdala.
• Possible deficiency of endogenous endocannabinoids in chronically traumatised individuals.
• THC has a dampening effect on neuronal hyperexcitability and emotional stress reactions.
• CBD potentially supports the extinction of learned fear responses via indirect pathways.

Risks and therapeutic limitations in trauma-related disorders

Despite the subjectively perceived relief, the use of cannabis for PTSD carries significant risks that must be carefully weighed in a therapeutic context. A central issue is the risk of psychological dependence, as affected individuals often use cannabis as a dysfunctional coping mechanism for acute crises. In addition, cannabis containing THC can trigger paranoid states, acute anxiety, or depersonalisation phenomena in vulnerable individuals. These paradoxical reactions worsen the already existing instability and can block or significantly delay the therapeutic processing of the trauma.

Another risk lies in the impairment of cognitive performance and memory due to regular consumption. Since successful trauma therapy is based on the active integration and processing of experiences, permanent dampening by cannabinoids can hinder the actual healing process. Medical cannabis should therefore never be understood as an isolated monotherapy, but exclusively as a supportive measure under close psychiatric supervision. Furthermore, the risk of interactions with other psychotropic substances requires a complete record of all prescribed medications.

• Increased risk of psychological dependence due to its use purely as a sedative.
• Risk of paradoxical reactions such as increased anxiety, paranoia, and dissociation.
• Possible blockage of therapeutic progress during psychotherapeutic trauma processing.
• Influence on cognitive performance and short-term memory during long-term use.

Swiss legal situation and medical prescribing practice

In Switzerland, the legal situation for patients changed fundamentally with the amendment to the law in August 2022. Since then, an exceptional licence from the Federal Office of Public Health (FOPH) is no longer required for prescribing medical cannabis with a total THC content of over one percent. The responsibility for determining the indication and prescribing lies entirely with the treating physicians. This liberalisation significantly facilitates access for severely affected PTSD patients for whom established therapeutic attempts did not bring sufficient relief, and enables standardised therapeutic trials with tested preparations.

Despite the simplified prescription process, those affected must observe essential legal framework conditions, particularly in road traffic. In Switzerland, a strict zero-tolerance practice applies to THC in the blood, with an analytical limit of 1.5 micrograms per litre. Even with a medically prescribed therapy, the fitness to drive legally expires if THC is detectable in the blood. Furthermore, cost coverage by the compulsory health insurance is not legally guaranteed. Health insurance funds decide on a case-by-case basis, based on a medical justification from the doctor, whether the costs will be covered under supplementary insurance or a goodwill arrangement.

• Medical prescription of THC-containing medicinal products without an FOPH exceptional licence since August 2022.
• Strict zero-tolerance in road traffic with a THC limit of 1.5 micrograms per litre of blood.
• Cost coverage by health insurance funds only occurs after a case-by-case review and medical justification.
• Use of controlled formulations from Swiss pharmacies to ensure patient safety.

FAQ